CpG oligonucleotide as an adjuvant for the treatment of prostate cancer

Advanced Drug Delivery Reviews

Volumn 61, Issue 3, 2009, Pages 268-274

  Lubaroff, David M ^a,b,c   Karan, Dev ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

CpG; Immunotherapy; Prostate cancer; Vaccine

Indexed keywords

CELL POPULATIONS; COLLAGEN MATRICES; CPG; EXPERIMENTAL ANIMALS; IMMUNE RESPONSE; IMMUNOTHERAPY; IN-VITRO; IN-VIVO; LONG TERMS; PROSTATE CANCER; PROSTATE TUMORS; T CELLS; TRANSGENIC ANIMALS; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS; CELL CULTURE; CELL PROLIFERATION; IMMUNIZATION; IMMUNOLOGY; OLIGONUCLEOTIDES; ONCOLOGY; TUMORS; VACCINES;

PEELING;

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR BETA GALACTOSIDASE COMPLEX; ADENOVIRUS VECTOR OVALBUMIN COMPLEX; ADENOVIRUS VECTOR PROSTATE SPECIFIC ANTIGEN VACCINE; BETA GALACTOSIDASE; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; OVALBUMIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BAGG ALBINO MOUSE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURVIVAL; TRANSGENIC MOUSE; TUMOR CELL; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CPG ISLANDS; IMMUNOTHERAPY; MALE; OLIGODEOXYRIBONUCLEOTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 61849089867     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.12.005     Document Type: Review

References (86)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J. Clin. 58 (2008) 71-96
2. Koostra N., and Verma I. Gene therapy with viral vectors. Annu. Rev. Immunol. 43 (2003) 413-439
3. Connolly J. Conditionally replicative viruses in cancer therapy. Gene Ther. 10 (2003) 712-715
4. Bronte V. Genetic vaccination for the active immunotherapy of cancer. Curr. Gene Ther. 1 (2001) 53-100
5. Chiocca E., and Smith E. Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin. Investig. Drugs 9 (2000) 311-327
6. Babiuk L., and Tikoo S. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J. Biotechnol. 83 (2000) 105-113
7. Zhang R. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6 (1999) 113-138
8. Siemens D., Elzey B., Lubaroff D., et al. Restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J. Immunol. 166 (2001) 731-735
9. Elzey B., Ratliff T., and Lubaroff D. Immunization with type 5 adenovirus recombinant for PSA in combination with ALVAC cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94 (2001) 842-849
10. Lubaroff D., Karan D., Andrews M., et al. Cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 24 (2006) 6155-6162
11. Karan D., Krieg A., and Lubaroff D. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite suppressed CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int. J. Cancer 121 (2007) 1520-1528
12. Cavacini L., Duval D., Elder J., et al. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin. Cancer Res. 8 (2002) 368-373
13. Sanda M., Smith D., Charles L., et al. Recombinant vaccinia-PSA (Prostvac) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53 (1999) 260-266
14. Eder J., Kantoff P., roper K., et al. A Phase I trail of recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6 (2000) 1632-1638
15. Meidenbauer N., Harris D., spitler L., et al. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43 (2000) 88-100
16. Heiser A., Coleman D., and Dannull J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109 (2002) 409-417
17. Gulley J., Chen A., Dahut W., et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53 (2002) 109-117
18. Kaufman H., Wang W., Manola J., et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22 (2004) 2122-2132
19. Pavlenko M., Roos A., Lundqvist A., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer 91 (2004) 688-694
20. Culley J., Arlen P., Bastian A., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11 (2005) 3353-3362
21. Small E., Fratesi P., Reese D., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18 (2000) 3894-3903
22. Fong L., Brockstedt B., Benike C., et al. Dendritic cell-based xenogeneic vaccination for prostate cancer immunotherapy. J. Immunol. 167 (2001) 7150-7156
23. Rini B. Technology innovation: APC-8015, Dendreon. Curr. Opin. Mol. Ther. 4 (2002) 78-79
24. Burch P., Croghan G., Gastineau D., et al. Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 60 (2004) 197-204
25. Tjoa B., Erickson S., Bowes V., et al. Follow-up evaluation of prostate cancer patients infused with Autologous dendritic cells pulsed with PSMA peptides. Prostate 32 (1997) 272-278
26. Tjoa B., Simmons S.S., Bowes V., et al. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36 (1998) 39-44
27. Murphy G., Tjoa B., Simmons S., et al. Infusion of dendritic cells pulsed with HLA-A2 specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine involving patients with hormone-refractory metastatic disease. Prostate 38 (1999) 73-78
28. Vonderheide R., Domchek S., Schultze J., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. 10 (2004) 828-839
29. Su Z., Dannull J., Yang B., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 174 (2005) 3798-3807
30. Slovin S., Ragupathi G., Musselli C., et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with RF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 54 (2005) 694-702
31. Slovin S., Ragupathi G., Musselli C., et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol. 21 (2003) 4292-4298
32. Slovin S., Ragupathi G., Adluri S., et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. 96 (1999) 5710-5715
33. + HRPC patients. Prostate 63 (2005) 1-12
34. Pandha H., Nohn R., Hutchinson L., et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumor lysate-pulsed cells: a phase I/II study. Br. J. Urol. 94 (2004) 41-418
35. Dreicer R., Ahman R., Pantuck A., et al. Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) in prostate cancer patients with biochemical failure. J. Clin. Oncol. 23 suppl. (2005) 4518
36. Small E., Schellhamer P., Higano C., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24 (2006) 3089-3094
37. Lubaroff D., Konety B., Link B., et al. A Phase I study of an adenovirus/PSA vaccine in men with metastatic prostate cancer. Hum. Gene Ther. 17 (2006) 220-229
38. Shahabi V., Reyes-Reyes M., Wallecha A., et al. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol. Immunother. 57 (2008) 1301-1313
39. Fenesterle J., Bergmann B., Yone C., et al. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther. 15 (2008) 85-93
40. Olson W., Heston W., and Rajeskaran A. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev. Recent Clin. Trials 2 (2007) 182-190
41. Zhang Z., Changming Y., Zhao J., et al. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. J. Gene Med. 9 (2007) 716-726
42. Morgenroth A., Cartellieri M., Schmitz M., et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67 (2007) 1121-1131
43. Olafsen T., Gu Z., Sherman M., et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J. Immunother. 30 (2007) 396-405
44. Patel P., and Kockler D. Sipuleucel-T (A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42 (2008) 91-98
45. Ross J., Sheehan C., Fisher H., et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 9 (2003) 6357-6362
46. Freeman L., Krynyckyi B., Li Y., et al. The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer. Q. J. Nucl. Med. 46 (2002) 131-137
47. Haseman M., Rosenthal S., and Polascik T. Capromab Pendetide imaging of prostate cancer. Cancer Biother. Radiopharm. 15 (2000) 131-140
48. Troyer J., Beckett M., and Wright Jr. G. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30 (1997) 232-242
49. Liu H., Moy P., Kim S., et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57 (1997) 3629-3634
50. Liu H., Rajasekaran A., Moy P., et al. Constitutive and antibody induced internalization of prostate-specific membrane antigen. Cancer Res. 58 (1998) 4055-4060
51. Murphy G., Tjoa B., Simmons S., et al. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43 (2000) 59-62
52. Lodge P., Jones L., Bader R., et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res. 60 (2000) 829-833
53. Salgaller M., Lodge P., McLean J., et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35 (1998) 144-151
54. Salgaller M., Tjoa B., Lodge P., et al. Dendritic cell-based immunotherapy of prostate cancer. Crit. Rev. Immunol. 18 (1998) 109-119
55. Tjoa B., Simmons S., Elgamal A., et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40 (1999) 125-129
56. Schulke N., Varlamova O., Donovan G., et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 12590-12595
57. Blachere N., and Srivastava P. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin. Cancer Biol. 6 (1995) 349-355
58. Srivastava P., Udono H., Blachere N., et al. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39 (1994) 93-98
59. Srivastava P., and Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6 (1994) 728-732
60. Simons J., Mikhak B., Chang J., et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59 (1999) 5160-5168
61. Small E., Sacks N., Neumanaitis J., et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 14 (2007) 3883-3891
62. Vollmer J., Weeratna R., Payette P., et al. Characterization of three CpG oligodeoxynucleotidea classes with distinct immunostimulatory activities. Eur. J. Immunol. 34 (2004) 251-262
63. Marciani D. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8 (2003) 934-943
64. Krieg A. Therapeutic potential of toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 (2006) 471-484
65. Krieg A. TLR9 and DNA "feel" rage. Nat. Immunol. 8 (2007) 475-477
66. McCluskie M., and Weeratna R. Novel adjuvant systems. Curr. Drug Targets Infect. Disord. 1 (2001) 263-271
67. Heit A., Schmitz F., O M., ' Keefe, et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174 (2005) 4373-4380
68. Gupta K., and Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drug R D 9 (2008) 137-145
69. Wang X., Bao R., Wan M., et al. A CpG oligodeoxynucleoide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine 26 (2008) 1893-1901
70. Belyakov I., Isakov D., Shu Q., et al. Enhancement of CD8+ T cell immunity in the lung of CpG oligodeoxynucleotides increases protective efficacy of a modified vaccine Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J. Immunol. 177 (2006) 6336-6343
71. Davila E., Kennedy R., and Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope pepride vaccination, CpG oligodeoxynucleotides adjuvant, and CTLA-4 blockade. Cancer Res. 64 (2003) 3281-3288
72. Daftarian P., Song G., ali S., et al. Distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res. 64 (2004) 5407-5414
73. Lonsdorf A., Kuekrek H., Stern B., et al. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor cell immunity. J. Immunol. 171 (2003) 3941-3946
74. Wu A., Oh S., Gharagozlou S., et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J. Immunother. 30 (2007) 789-797
75. Nokavoki S., Stegel V., Kopitar A., et al. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine 25 (2007) 8241-8256
76. song S., Wang Y., Zhang Y., et al. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG. Cancer Lett. 256 (2007) 90-100
77. Woo S., Kim C., Park M., et al. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci. 99 (2008) 1034-1039
78. Appay V., Jandus C., Voelter V., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J. Immunol. 177 (2006) 1670-1678
79. Pilon-thomas S., Li W., Briggs J., et al. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J. Immunother. 29 (2006) 381-387
80. Jerome V., Graser A., Muller R., et al. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposomeencapsulated. J. Immunother. 29 (2006) 294-305
81. Shi R., Hong L., Wu D., et al. Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion. Cancer Biol. Ther. 4 (2005) 218-224
82. Hiroaka K., Yamamoto S., Otsuru S., et al. Enhanced tumor-specific long-term immunity of hemaggluttinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol. 173 (2004) 4297-4307
83. Switaj T., Jalili A., Jakubowska A., et al. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer Res. 10 (2004) 4165-4172
84. Baines J., and Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin. Cancer Res. 9 (2003) 2693-2700
85. Ballas Z., Krieg A., Warren T., et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167 (2001) 4878-4886
86. Wingender G., Garbi N., Schumak B., et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36 (2006) 12-20